目次

Table of Content

1. Introduction To Gamma Delta T Cell Therapy
1.1 Emerging Role of T Cell Based Immunotherapies
1.2 Overview of Gamma Delta T Cell Therapy
1.3 Gamma Delta T Cell Therapy v/s Conventional Therapies

2. Role of Gamma Delta T Cells in Cancer
2.1 Gamma Delta T Cells in Cancer Progression
2.2 Anti Tumor Activity of Gamma Delta T Cells
2.3 Adopted Approaches for Gamma Delta T Cell Therapy

3. Advanced Combination Strategies In Gamma Delta T Cell Therapy

4. Gamma Delta T Cell Therapy Market Overview
4.1 Current Market Scenario
4.2 Future RandD and Commercial Opportunities
4.3 Market Potential of Gamma Delta T Cell Therapy Market
4.4 Technology Platforms For Gamma Delta T Cell Therapy
4.5 Favorable Market Growth Parameters
4.6 Key Challenges To Overcome For Future Growth

5. Global Gamma Delta T Cell Therapy Clinical Trials Overview
5.1 By Phase
5.2 By Country
5.3 By Company
5.4 By Indication
5.5 By Priority Status

6. Global Gamma Delta T Cell Therapy Clinical Trials Insight By Company, Country, Indication and Phase
6.1 Research
6.2 Preclinical
6.3 Phase I
6.4 Phase I/II
6.5 Phase II
6.6 Phase II/III

7. Gamma Delta T Cell Therapy in Leukemia
7.1 Ongoing Clinical Research and Development Trends
7.2 Future Market Opportunity of Gamma Delta T Cells in Leukemia

8. Gamma Delta T Cell Therapy in Lung Cancer
8.1 Ongoing Clinical Research and Development Trends
8.2 Future Market Opportunity of Gamma Delta T Cell Therapy in Lung Cancer

9. Gamma Delta T Cells in Breast Cancer
9.1 Ongoing Clinical Research and Development Trends
9.2 Future Market Opportunity of Gamma Delta T Cell Therapy in Breast Cancer

10. Gamma Delta T Cells in Colorectal Cancer
10.1 Ongoing Clinical Research and Development Trends
10.2 Future Market Potential of Gamma Delta T Cell Therapy in Colorectal Cancer

11. Gamma Delta T Cells in Pancreatic Cancer
11.1 Ongoing Clinical Research and Development Trends
11.2 Future Market Potential of Gamma Delta Therapy in Pancreatic Cancer

12. Gamma Delta T Cells in Lymphoma
12.1 Ongoing Clinical Research and Development Trends
12.2 Future Market Potential of Gamma Delta Therapy in Lymphoma

13. Gamma Delta T Cell Therapy in Brain Tumors
13.1 Research and Development in Brain Tumors
13.2 Future Market Potential of Gamma Delta Therapy in Brain Tumors

14. Gamma Delta T Cell Therapy in Head and Neck Cancer
14.1 Research and Development in Head and Neck Cancer
14.2 Future Market Potential of Gamma Delta Therapy in Head and Neck Cancer

15. Competitive Landscape
15.1 Acepodia
15.2 Adicet
15.3 Appia Bio
15.4 Cytomed Therapeutics
15.5 Century Therapeutics
15.6 Expression Therapeutics
15.7 Immatics
15.8 IN8bio
15.9 JY BioMed
15.10 Legend Biotech
15.11 Luminary Therapeutics
15.12 PhosphoGam
15.13 Takeda
15.14 TC Biopharm
15.15 ViGenCell

List of Figures & Tables
Figure 1-1: History Of T Cell Based Immunotherapy
Figure 1-2: Gamma Delta T cell Therapy
Figure 1-3: Stimulants of Gamma Delta T Cells
Figure 1-4: CAR T Cell Therapy Limitations
Figure 1-5: Limitations of TIL
Figure 1-6: Limitations of Monoclonal Antibodies
Figure 1-7: Drawbacks of Chemotherapeutic Drugs
Figure 2-1: Pro-Tumor Role of Gamma Delta T Cells
Figure 2-2: Antigen Presentation Functions Of Gamma Delta T Cells
Figure 2-3: Anti-Tumor Activity of Gamma Delta T-Cells
Figure 2-4: Gamma Delta T Cell Bispecific Antibodies - Mechanism of Action
Figure 2-5: Functional Advantages Of andgamma;anddelta; T Cells for CAR T Cancer Therapy
Figure 2-6: CAR andgamma;anddelta; T Cells - Mechanism of Action
Figure 4-1: Gamma Delta T Cell Therapy Market - Future Opportunities
Figure 4-2: Global - Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-3: Global - Gamma Delta T Cell Therapy Market Opportunity By 1% Of Total Cell Therapy Market (US$ Billion), 2025 -2031
Figure 4-4: Global - Gamma Delta T Cell Therapy Market Opportunity By 2% Of Total Cell Therapy Market (US$ Billion), 2025 -2031
Figure 4-5: Global - Gamma Delta T Cell Therapy Market Opportunity By 3% Of Total Cell Therapy Market (US$ Billion), 2025 -2031
Figure 4-6: Global - Gamma Delta T Cell Therapy Market Opportunity By 4% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-7: Global - Gamma Delta T Cell Therapy Market Opportunity By 5% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-8: Global - Gamma Delta T Cell Therapy Market Opportunity By 6% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-9: Global - Gamma Delta T Cell Therapy Market Opportunity By 7% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-10: Global - Gamma Delta T Cell Therapy Market Opportunity By 8% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-11: Global - Gamma Delta T Cell Therapy Market Opportunity By 9% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-12: Global - Gamma Delta T Cell Therapy Market Opportunity By 10% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-13: IN8bio - DeltEx DRI Auto
Figure 4-14: Diamond AI - Prediction Engine
Figure 4-15: Diamond AI - Immune Surveillance
Figure 4-16: Acepodia - Antibody-Cell Conjugation
Figure 4-17: Lava Therapeutics - Gammabody Platform
Figure 4-18: Adicet Bio - Gamma Delta Cell Platform
Figure 4-19: ADI-001 - Gamma Delta Cell Therapy
Figure 4-20: Century Therapeutics - Allo-Evasion
Figure 4-21: ViGenCell - ViRanger Platform
Figure 4-22: Legend Biotech - CAR-andgamma;anddelta; T Platform
Figure 4-23: Immatics - ACTalloandreg; Manufacturing Process
Figure 4-24: Gamma Delta T Cell Platform - carxall
Figure 4-25: Proprietary Manufacturing and Cell Platform Process - Adicet Bio
Figure 4-26: CAR-andgamma;anddelta; T Cell - CytoMed Therapeutics
Figure 4-27: iPSC-andgamma;anddelta; NKT Cells - CytoMed Therapeutics
Figure 4-28: Luminary Therapeutics - TcBuster Benefits
Figure 4-29: SSC Cell Platform - Core Foundations
Figure 4-30: Acua Platform - Appia Bio
Figure 4-31: Gamma Delta T Cell Therapy Market Drivers and Opportunities
Figure 4-32: Gamma Delta T Cell Therapy Market Challenges and Restraints
Figure 5-1: Global - Gamma Delta T Cell Therapy Clinical Trials By Phase (Numbers), 2025 Till 2031
Figure 5-2: Global - Gamma Delta T Cell Therapy Clinical Trials By Country (Numbers), 2025 Till 2031
Figure 5-3: Global - Gamma Delta T Cell Therapy Clinical Trials By Company (Numbers), 2025 Till 2031
Figure 5-4: Global - Gamma Delta T Cell Therapy Clinical Trials By Indication (Numbers), 2025 Till 2031
Figure 5-5: Global - Gamma Delta T Cell Therapy Clinical Trials By Priority Status (Numbers), 2025 Till 2031
Figure 7-1: Benefits of Gamma Delta T Cells in Leukemia
Figure 7-2: CD33CART Phase 1/2 (NCT03971799) Study - Initiation and Completion Year
Figure 7-3: ACHIEVE (TCB008-001) Phase 2 (NCT05358808) Study - Initiation and Completion Year
Figure 7-4: ACHIEVE2 (TCB008-003) Phase 1 (NCT06463327) Study - Initiation and Completion Year
Figure 7-5: INB-100 Phase 1 (NCT03533816) Study - Initiation and Completion Year
Figure 7-6: Mechanism of Action of Vandgamma;9/CD123 Bispecific Antibody
Figure 7-7: Global - Estimated Leukemia Cases, 2025-2031
Figure 7-8: US - Estimated Leukemia Cases, 2025-2031
Figure 7-9: Europe - Estimated Leukemia Cases, 2025-2031
Figure 7-10: China - Estimated Leukemia Cases, 2025-2031
Figure 7-11: Japan - Estimated Leukemia Cases, 2025-2031
Figure 8-1: Role of Gamma Delta T Cells in Lung Cancer
Figure 8-2: DELTACEL-01 Phase 1 (NCT06069570) Study - Initiation and Completion Year
Figure 8-3: Global - Estimated Lung Cancer Cases, 2025-2031
Figure 8-4: US - Estimated Lung Cancer Cases, 2025-2031
Figure 8-5: Europe - Estimated Lung Cancer Cases, 2025-2031
Figure 8-6: China - Estimated Lung Cancer Cases, 2025-2031
Figure 8-7: Japan - Estimated Lung Cancer Cases, 2025-2031
Figure 9-1: Global - Estimated Breast Cancer Cases, 2025-2031
Figure 9-2: US - Estimated Breast Cancer Cases, 2025-2031
Figure 9-3: Europe - Estimated Breast Cancer Cases, 2025-2031
Figure 9-4: China - Estimated Breast Cancer Cases, 2025-2031
Figure 9-5: Japan - Estimated Breast Cancer Cases, 2025-2031
Figure 10-1: Role of Gamma Delta T Cells in Colorectal Cancer
Figure 10-2: Mechanism Underlying B7-H3 Regulating andgamma;anddelta; T Cells Killing Colon Cancer Cells
Figure 10-3: SGNEGFRd2-001 Phase I (NCT05983133) Study - Initiation and Completion Year
Figure 10-4: Global - Estimated Colorectal Cancer Cases, 2025-2031
Figure 10-5: US - Estimated Colorectal Cancer Cases, 2025-2031
Figure 10-6: Europe - Estimated Colorectal Cancer Cases, 2025-2031
Figure 10-7: China - Estimated Colorectal Cancer Cases, 2025-2031
Figure 10-8: Japan - Estimated Colorectal Cancer Cases, 2025-2031
Figure 11-1: Auspicious Outcomes Gamma Delta T Cell Therapy
Figure 11-2: Role of Gamma Delta T Cells in Pancreatic Cancer Progression
Figure 11-3: Global - Estimated Pancreatic Cancer Cases, 2025-2031
Figure 11-4: US - Estimated Pancreatic Cancer Cases, 2025-2031
Figure 11-5: Europe - Estimated Pancreatic Cancer Cases, 2025-2031
Figure 11-6: China - Estimated Pancreatic Cancer Cases, 2025-2031
Figure 11-7: Japan - Estimated Pancreatic Cancer Cases, 2025-2031
Figure 12-1: ACE1831 Phase I (NCT05653271) Study - Initiation and Completion Year
Figure 12-2: ADI-001 Phase I (NCT04735471) Study - Initiation and Completion Year
Figure 12-3: Global - Estimated Lymphoma Cases, 2025-2031
Figure 12-4: US - Estimated Lymphoma Cases, 2025-2031
Figure 12-5: Europe - Estimated Lymphoma Cases, 2025-2031
Figure 12-6: China - Estimated Lymphoma Cases, 2025-2031
Figure 12-7: Japan - Estimated Lymphoma Cases, 2025-2031
Figure 13-1: INB-400 Phase 1/2 (NCT05664243) Study - Initiation and Completion Year
Figure 13-2: IN8bio - Autologous (INB-400) and Allogeneic (INB-410) Candidates
Figure 13-3: UAB 1773 Phase 1 (NCT04165941) Study - Initiation and Completion Year
Figure 13-4: Global - Estimated Brain Cancer Cases, 2025-2031
Figure 13-5: US - Estimated Brain Tumor Cases, 2025-2031
Figure 13-6: Europe - Estimated Brain Tumor Cases, 2025-2031
Figure 13-7: China - Estimated Brain Tumor Cases, 2025-2031
Figure 13-8: Japan - Estimated Brain Tumor Cases, 2025-2031
Figure 14-1: Acepodia Biotech Clinical Pipeline Insight
Figure 14-2: Pfizer and Lava Therapeutics Collaboration
Figure 14-3L: SGN-EGFRd2 Phase 1 (NCT05983133) Study - Initiation and Completion Year
Figure 14-4: Global - Estimated Head and Neck Cancer Cases, 2025-2031
Figure 14-5: US - Estimated Head and Neck Cancer Cases, 2025-2031
Figure 14-6: Europe - Estimated Head and Neck Cancer Cases, 2025-2031
Figure 14-7: China - Estimated Head and Neck Cancer Cases, 2025-2031
Figure 14-8: Japan - Estimated Head and Neck Cancer Cases, 2025-2031
Table 3-1: Ongoing Clinical Trials For Combination Of Gamma Delta T Cell Therapy
Table 7-1: Global - Estimated Adoption Rate Of Gamma Delta T Cell In Leukemia, 2025-2031
Table 7-2: US - Estimated Adoption Rate Of Gamma Delta T Cell In Leukemia, 2025-2031
Table 7-3: Europe - Estimated Adoption Rate Of Gamma Delta T Cell In Leukemia, 2025-2031
Table 7-4: China - Estimated Adoption Rate Of Gamma Delta T Cell In Leukemia, 2025-2031
Table 7-5: Japan - Estimated Adoption Rate Of Gamma Delta T Cell In Leukemia, 2025-2031
Table 8-1: Global - Estimated Adoption Rate Of Gamma Delta T Cell In Lung Cancer, 2025-2031
Table 8-2: US - Estimated Adoption Rate Of Gamma Delta T Cell In Lung Cancer, 2025-2031
Table 8-3: Europe - Estimated Adoption Rate Of Gamma Delta T Cell In Lung Cancer, 2025-2031
Table 8-4: China - Estimated Adoption Rate Of Gamma Delta T Cell In Lung Cancer, 2025-2031
Table 8-5: Japan - Estimated Adoption Rate Of Gamma Delta T Cell In Lung Cancer, 2025-2031
Table 9-1: Global - Estimated Adoption Rate Of Gamma Delta T Cell In Breast Cancer, 2025-2031
Table 9-2: US - Estimated Adoption Rate Of Gamma Delta T Cell In Breast Cancer, 2025-2031
Table 9-3: Europe - Estimated Adoption Rate Of Gamma Delta T Cell In Breast Cancer, 2025-2031
Table 9-4: China - Estimated Adoption Rate Of Gamma Delta T Cell In Breast Cancer, 2025-2031
Table 9-5: Japan - Estimated Adoption Rate Of Gamma Delta T Cell In Breast Cancer, 2025-2031
Table 10-1: Global - Estimated Adoption Rate Of Gamma Delta T Cell In Colorectal Cancer, 2025-2031
Table 10-2: US - Estimated Adoption Rate Of Gamma Delta T Cell In Colorectal Cancer, 2025-2031
Table 10-3: Europe - Estimated Adoption Rate Of Gamma Delta T Cell In Colorectal Cancer, 2025-2031
Table 10-4: China - Estimated Adoption Rate Of Gamma Delta T Cell In Colorectal Cancer, 2025-2031
Table 10-5: Japan - Estimated Adoption Rate Of Gamma Delta T Cell In Colorectal Cancer, 2025-2031
Table 11-1: Global - Estimated Adoption Rate Of Gamma Delta T Cell In Pancreatic Cancer, 2025-2031
Table 11-2: US - Estimated Adoption Rate Of Gamma Delta T Cell In Pancreatic Cancer, 2025-2031
Table 11-3: Europe - Estimated Adoption Rate Of Gamma Delta T Cell In Pancreatic Cancer, 2025-2031
Table 11-4: China - Estimated Adoption Rate Of Gamma Delta T Cell In Pancreatic Cancer, 2025-2031
Table 11-5: Japan - Estimated Adoption Rate Of Gamma Delta T Cell In Pancreatic Cancer, 2025-2031
Table 12-1: Global - Estimated Adoption Rate Of Gamma Delta T Cell In Lymphoma, 2025-2031
Table 12-2: US - Estimated Adoption Rate Of Gamma Delta T Cell In Lymphoma, 2025-2031
Table 12-3: Europe - Estimated Adoption Rate Of Gamma Delta T Cell In Lymphoma, 2025-2031
Table 12-4: China - Estimated Adoption Rate Of Gamma Delta T Cell In Lymphoma, 2025-2031
Table 12-5: Japan - Estimated Adoption Rate Of Gamma Delta T Cell In Lymphoma, 2025-2031
Table 13-1: Global - Estimated Adoption Rate Of Gamma Delta T Cell In Brain Tumors, 2025-2031
Table 13-2: US - Estimated Adoption Rate Of Gamma Delta T Cell In Brain Tumors, 2025-2031
Table 13-3: Europe - Estimated Adoption Rate Of Gamma Delta T Cell In Brain Tumors, 2025-2031
Table 13-4: China - Estimated Adoption Rate Of Gamma Delta T Cell In Brain Tumors, 2025-2031
Table 13-5: Japan - Estimated Adoption Rate Of Gamma Delta T Cell In Brain Tumors, 2025-2031
Table 14-1: Global - Estimated Adoption Rate Of Gamma Delta T Cell In Head and Neck Cancers, 2025-2031
Table 14-2: US - Estimated Adoption Rate Of Gamma Delta T Cell In Head and Neck Cancers, 2025-2031
Table 14-3: Europe - Estimated Adoption Rate Of Gamma Delta T Cell In Head and Neck Cancer, 2025-2031
Table 14-4: China - Estimated Adoption Rate Of Gamma Delta T Cell In Head and Neck Cancers, 2025-2031
Table 14-5: Japan - Estimated Adoption Rate Of Gamma Delta T Cell In Head and Neck Cancer, 2025-2031